Granules India’s Gagillapur unit successfully completed USFDA inspection

India Infoline News Service | Mumbai | October 17, 2016 08:46 IST

The company informed BSE that Gagillapur facility located at Hyderabad, Telangana, India has successfully completed US FDA inspection without any observations.

Granules India
Granules India Ltd has informed BSE that Gagillapur facility located at Hyderabad, Telangana, India has successfully completed US FDA inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

Stock Commentary:

Granules India Ltd ended at Rs 120, up by Rs 0.8 or 0.67% from its previous closing of Rs 119.2 on the BSE.

The scrip opened at Rs 120 and touched a high and low of Rs 120.95 and Rs 119.5 respectively. A total of 698029(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2605.94 crore.

The BSE group 'B' stock of face value Rs 1 touched a 52 week high of Rs 164.45 on 01-Dec-2015 and a 52 week low of Rs 101.25 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs 122 and Rs 117.75 respectively.

The promoters holding in the company stood at 51.04 % while Institutions and Non-Institutions held 9.09 % and 39.87 % respectively.

The stock traded below its 200 DMA.

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.